论文部分内容阅读
目的:通过研究阿托伐他汀对急性心肌梗死(AMI)患者无复流现象中脑钠肽的影响,探讨阿托伐他汀在无复流的作用。方法:根据造影结果将98例行急诊冠状动脉介入治疗的AMI患者分为无复流组和血流正常组,应用酶联免疫吸附法检测患者入院时的血浆脑利钠肽(BNP)、高敏C反应蛋白(hs-CRP)。结果:与血流正常组相比,AMI无复流组患者BNP、CRP显著增高(P<0.05),左室射血分数显著减低,无复流组患者术前他汀类药物使用比例显著减少(P<0.05)。结论:BNP、CRP可能是冠状动脉无复流现象发生的预测因素之一,他汀类干预可以显著减少无复流现象的发生。
Objective: To investigate the effect of atorvastatin on brain natriuretic peptide in patients with acute myocardial infarction (AMI) with no-reflow phenomenon and to explore the effect of atorvastatin on no-reflow phenomenon. Methods: According to the angiographic results, 98 AMI patients undergoing emergency PCI were divided into no-reflow group and normal blood flow group. Enzyme-linked immunosorbent assay (ELISA) was used to detect plasma brain natriuretic peptide (BNP) C-reactive protein (hs-CRP). Results: Compared with normal blood flow group, BNP and CRP in patients with AMI without recurrence were significantly increased (P <0.05), left ventricular ejection fraction was significantly decreased, and the proportion of preoperative statin use was significantly decreased P <0.05). Conclusion: BNP and CRP may be one of the predictors of coronary artery no-reflow phenomenon. Statin intervention can significantly reduce the occurrence of no-reflow phenomenon.